Navigation Links
Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
Date:1/20/2009

THOUSAND OAKS, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it plans to report its fourth quarter and full year financial results on Monday, Jan. 26, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call, including the question and answer session, is expected to last approximately one hour.

The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's Web site, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay 72 hours after the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 (media)
    Arvind Sood, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
2. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
3. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Call for Applications: The Amgen Award for Science Teaching Excellence
6. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
9. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
10. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
11. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 ... at four equities in the Biotech industry: Sangamo Therapeutics ... Biologics Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. ... st , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology ... downloading their free report at: ...
(Date:3/22/2017)... N.Y. , March 22, 2017 Regeneron Pharmaceuticals, ... the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to ... the U.K. Biobank resource. The initiative will enable researchers to ... new medicines for a wide range of serious and life ... ...
(Date:3/22/2017)...  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... address significant unmet medical needs in rare diseases, ... ended December 31, 2016. "2016 ... we broadened our pipeline and pursued our vision ... with an initial focus on endocrinology," said ...
(Date:3/22/2017)... March 22, 2017 Good Start Genetics, a ... eclipsed the 130 million covered lives mark through its ... Texas . With newly signed contracts ... to enjoy strong payor acceptance based on the quality ... and genetic counseling, its industry-leading customer care and support ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
Breaking Biology News(10 mins):